Targeted Radiopeptides

Direct to tumor Radiotheranostics

We use the ModelMole platform to develop our own peptide‑based radiotheranostics for overexpressed cancer targets.

These peptides bind to cancer in the body and deliver the radioactive payload directly to the cancer site, maximizing tumor damage while minimizing radiation exposure to healthy tissues.

This approach offers a more effective therapy, and a more economical manufacturing process compared to antibody-based therapies, ultimately leading to improved patient outcomes and increased access to precision radiotherapy.

Each Radiopeptide has 3 objectives:

✅ Survive boiling in acid at 95°C (to quickly bind radioion)

✅ Strongly bind radioactive ions

✅ Target cancer cells

Molecular structure illustration showing a drug molecule binding to a receptor site.

  • FT-01-002

    ✓ Cancer Binding Affinity: 0.1 - 1.0 nM

    ✓ Stable (Acidity + 95°C)

    ✓ Radiochemical Purity > 95%

  • FT-01-005

    ✓ Cancer Binding Affinity: 0.1 - 1.0 nM

    ✓ Stable (Acidity + 95°C)

    ✓ Radiochemical Purity > 95%

Traditional computational screening methods yielded zero viable candidates (blue line), while ModelMole's AI approach dramatically increases the probability of discovering high-quality hits (purple line).

The graph illustrates how our AI method produces significantly more promising candidates than the conventional approaches we tested.